Global Anti-Neprilysin Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The Global Anti-Neprilysin Market has been segmented by Drug, Indication, Application, and Geography, each providing valuable insight into the various factors influencing the market's growth. In terms of Drug, the market primarily revolves around sacubitril/valsartan, a combination therapy that is used to treat heart failure with reduced ejection fraction (HFrEF). This drug works by inhibiting neprilysin, an enzyme responsible for breaking down natriuretic peptides, thereby helping to relax blood vessels and reduce the workload on the heart. Other drugs in the anti-neprilysin category may include investigational therapies currently under clinical trials or awaiting approval, but sacubitril/valsartan remains the leading drug in this market.

The market is also segmented by Indication, with the primary indication being heart failure, particularly heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan is used to manage this condition by improving symptoms, reducing hospitalizations, and enhancing survival rates. Additionally, anti-neprilysin drugs are being explored for other potential indications, including chronic kidney disease, diabetic nephropathy, and acute myocardial infarction. As research progresses, new indications could emerge, further expanding the market and the range of diseases treated with neprilysin inhibitors. The growing understanding of the benefits of neprilysin inhibition beyond heart failure is likely to drive the development of additional therapies targeting these areas.

In terms of Application, the Global Anti-Neprilysin Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are the primary distribution channel, especially for severe cases of heart failure, where patients require careful monitoring and administration of prescribed treatments like sacubitril/valsartan. Retail Pharmacies play a key role in providing anti-neprilysin drugs to patients on a long-term basis, where they can access their prescriptions for regular refills. Online Pharmacies have gained traction in recent years, offering the convenience of home delivery for patients, especially those who may have difficulty visiting traditional pharmacies due to mobility issues or geographic constraints. As the adoption of digital health technologies and telemedicine rises, the market for anti-neprilysin drugs through online platforms is expected to grow further.

Geographically, the Global Anti-Neprilysin Market is primarily driven by North America, particularly the United States, where heart failure is a leading cause of morbidity and mortality. The approval and widespread use of sacubitril/valsartan have significantly impacted the market in this region. Europe also represents a large share of the market, with an increasing number of countries adopting anti-neprilysin therapies as part of their standard treatment protocols for heart failure. Asia-Pacific is expected to witness rapid growth in the market due to the rising incidence of heart failure, increased healthcare access, and growing awareness of innovative treatments. Latin America and Middle East & Africa are emerging markets where the anti-neprilysin drugs' usage is expanding, although challenges such as affordability and access may limit faster adoption in these regions. Overall, the global market for anti-neprilysin drugs is poised for continued expansion due to the increasing prevalence of heart failure and ongoing research into additional therapeutic indications.

Global Anti-Neprilysin Segment Analysis

In this report, the Global Anti-Neprilysin Market has been segmented by Drug, Indication, Applicatuion and Geography.

Global Anti-Neprilysin Market, Segmentation by Drug

The Global Anti-Neprilysin Market has been segmented by Drug into Sacubitril, TD-0714, STR-324, PL-265, and LHW-090.

Sacubitril, often combined with valsartan to form an angiotensin receptor neprilysin inhibitor (ARNI), is widely used and has revolutionized the treatment of chronic heart failure by significantly reducing hospitalization rates and mortality. It remains the most prominent and commercially successful neprilysin inhibitor currently available.

TD-0714 is another promising neprilysin inhibitor, which is currently under clinical investigation. This drug is being studied for its potential to provide improved efficacy and safety profiles, expanding the therapeutic options for patients with cardiovascular conditions.

STR-324 represents a novel class of neprilysin inhibitors, focusing on a different mechanism of action that could potentially offer unique benefits over existing treatments. It is being researched for its application in various cardiovascular and renal disorders.

PL-265 is in the developmental pipeline, aimed at addressing unmet medical needs in treating heart failure and other related conditions. It holds promise for future use due to its innovative approach to neprilysin inhibition.

LHW-090 is an emerging drug candidate in the anti-neprilysin market. As it progresses through clinical trials, it is expected to contribute to the diversification of treatment options available to healthcare providers, particularly in managing chronic cardiovascular diseases.

Global Anti-Neprilysin Market, Segmentation by Indication

The Global Anti-Neprilysin Market has been segmented by Indication into Acute Heart Failure, Cancer Pain, Hypertension, Alzheimers Disease, and Others.

Acute Heart Failure is a primary indication for anti-neprilysin drugs, particularly with the use of Sacubitril in combination with valsartan. This combination therapy has significantly improved patient outcomes by reducing hospitalization rates and mortality in heart failure patients.

Cancer Pain management is an emerging indication for anti-neprilysin inhibitors. Research is ongoing to explore their potential in alleviating severe pain associated with cancer, providing a new avenue for supportive cancer care.

Hypertension is another critical indication where anti-neprilysin drugs are being evaluated for their ability to lower blood pressure effectively. These inhibitors may offer an additional treatment option for patients who are resistant to conventional antihypertensive therapies.

Alzheimer’s Disease is being investigated as a potential indication for neprilysin inhibitors. The rationale is based on neprilysin’s role in degrading amyloid-beta peptides, which are implicated in the pathogenesis of Alzheimer’s disease. This application could pave the way for novel treatments aimed at slowing or preventing disease progression.

Other indications include a range of cardiovascular and renal disorders where neprilysin inhibition could provide therapeutic benefits. These may involve conditions such as chronic kidney disease, pulmonary hypertension, and other related ailments.

Global Anti-Neprilysin Market, Segmentation by Application

In this report, the Global Anti-Neprilysin Market has been segmented by Application into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

The Global Anti-Neprilysin Market has been segmented by Application into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies play a significant role in the distribution of anti-neprilysin drugs, especially given that these therapies are often prescribed for patients with heart failure and other serious conditions that require continuous monitoring. Hospital pharmacies ensure that patients receive the correct dosage and provide medications in a controlled setting where healthcare professionals can track their progress and manage potential side effects. This segment is crucial for the distribution of prescription-only anti-neprilysin drugs like sacubitril/valsartan, a combination therapy used in heart failure management.

On the other hand, Retail Pharmacies and Online Pharmacies have seen growing importance in the market, as patients with chronic conditions like heart failure increasingly manage their medication independently. Retail Pharmacies provide easy access to anti-neprilysin drugs, where patients can obtain their prescriptions with the assistance of pharmacists for consultation. Online Pharmacies, which have expanded in recent years, offer a convenient alternative for purchasing anti-neprilysin medications, especially for individuals who may have difficulty accessing traditional brick-and-mortar stores. The rise of telemedicine and the growing preference for home-based healthcare are also contributing to the increasing importance of online pharmacies in delivering these specialized treatments to a wider patient base.

Global Anti-Neprilysin Market, Segmentation by Geography

In this report, the Global Anti-Neprilysin Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Anti-Neprilysin Market Share (%), by Geographical Region, 2024

North America dominates the anti-neprilysin market due to its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong presence of key pharmaceutical companies. The region’s focus on innovative drug development and extensive research activities further drives market growth.

Europe is a significant market for anti-neprilysin drugs, supported by increasing healthcare expenditure, a rising aging population, and a growing incidence of chronic diseases. The region's regulatory framework also facilitates the adoption of new therapies.

Asia Pacific is experiencing rapid market growth, driven by improving healthcare infrastructure, increasing awareness about chronic diseases, and a large patient pool. Countries like China and India are emerging as key markets due to their expanding healthcare sectors and rising investments in medical research.

The Middle East and Africa region presents opportunities for market expansion due to the increasing burden of cardiovascular diseases and efforts to improve healthcare services. Market growth is somewhat restrained by limited access to advanced treatments and healthcare infrastructure challenges.

Latin America is gradually emerging as a market for anti-neprilysin drugs, with improving healthcare facilities and growing awareness about cardiovascular health. Economic development and healthcare reforms in countries like Brazil and Mexico are expected to boost market growth in the region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Anti-Neprilysin Market. These factors include; Market Drivers, Restraints, and Opportunities.

Drivers:

• Rising cardiovascular disease prevalence
• Aging population
• Drug development advancements
• Increased cardiovascular health awareness

• Combination therapy adoption - Combination therapy adoption in the global anti-neprilysin market represents a significant driver fueling advancements in treatment approaches. Physicians increasingly recognize the potential benefits of combining multiple drugs with complementary mechanisms of action to enhance therapeutic outcomes. This approach allows for synergistic effects, targeting different pathways involved in the disease process simultaneously.

  In conditions such as heart failure and hypertension, where neprilysin inhibition has shown promising results, combining anti-neprilysin drugs with other cardiovascular medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) can lead to improved patient management. Combination therapy offers the potential for greater efficacy, better symptom control, and reduced adverse effects compared to monotherapy.

  Healthcare providers are also becoming more adept at tailoring treatment regimens to individual patient needs, considering factors such as disease severity, comorbidities, and medication tolerance. This personalized approach to therapy encourages the exploration of combination therapies as a means to optimize patient outcomes and improve quality of life.

Restraints:

• Regulatory hurdles
• Limited rural healthcare access
• Safety concerns
• Healthcare professional resistance

• Patient adherence challenges - Patient adherence challenges pose a significant restraint in the global anti-neprilysin market. Despite the potential benefits of anti-neprilysin therapy, ensuring patient adherence to treatment regimens can be challenging. Factors such as complex dosing schedules, polypharmacy, and medication side effects may contribute to non-adherence among patients.

  Additionally, the chronic nature of conditions targeted by anti-neprilysin drugs, such as heart failure and hypertension, requires long-term medication adherence for optimal outcomes. Patients may struggle to adhere to prescribed treatment plans due to various reasons, including forgetfulness, perceived lack of efficacy, or concerns about potential adverse effects.

  Addressing patient adherence challenges requires a multifaceted approach that encompasses patient education, medication management strategies, and healthcare provider support. By implementing interventions such as patient education programs, medication reminders, and regular follow-up appointments, healthcare providers can help improve adherence rates and optimize treatment outcomes in the anti-neprilysin market.

Opportunities:

• Collaboration opportunities
• Digital health integration
• Combination therapy development
• Personalized medicine advancements

• Value-based care adoption - Value-based care adoption presents a significant opportunity in the global anti-neprilysin market. As healthcare systems worldwide transition toward value-based care models, there is a growing emphasis on achieving better patient outcomes while reducing healthcare costs. Anti-neprilysin drugs, with their potential to improve cardiovascular and other health outcomes, align well with the goals of value-based care.

  Value-based care models incentivize healthcare providers to prioritize preventive measures, chronic disease management, and interventions that yield the best outcomes for patients. Anti-neprilysin therapies, known for their efficacy in conditions like heart failure, hypertension, and Alzheimer's disease, can contribute to better patient health outcomes and quality of life.

  Value-based care models promote care coordination, patient engagement, and population health management, all of which are essential components for optimizing the use of anti-neprilysin drugs. By implementing care pathways that incorporate anti-neprilysin therapy as part of comprehensive treatment strategies, healthcare providers can better manage chronic conditions and prevent disease progression.

Key players in Global Anti-Neprilysin Market include,

• Novartis AG
• Bristol Myers Squibb Company
• Pfizer Inc.
• AstraZeneca plc
• Merck & Co., Inc.
• Johnson & Johnson
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Company, Limited
• Bayer AG
• GlaxoSmithKline plc
• AbbVie Inc.
• Sanofi S.A.
• Amgen Inc.
• Eli Lilly and Company

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis